Harald Gross receives the 2022 PHOENIX Pharmaceutical Science Award in the category Pharmaceutical Biology
The pharmacist is, together with the two further TRR members Evi Stegmann and Wolfgang Wohlleben, honored for the biotechnological development of a production platform for the immunosuppressive natural product brasilicardin A. Since common immunosuppressants in clinical use still have severe side effects, new agents, preferably with novel modes of action are needed. Brasilicardin A represents such a candidate molecule but was so far not available for follow-up investigations. The combined efforts of the team members overcame this obstacle and paved the way for the generation of optimized derivatives and conducted the first preclinical studies.
Group picture of the recipients of the 2022 PHOENIX Pharmaceutical Science Award (from the left to the right): Prof. Wolfgang Wohlleben, Prof. Evi Stegmann, Prof. Harald Gross and Dr. Anina Buchmann (© PHOENIX group).